Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial

An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitam...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 5; no. 9; p. e12244
Main Authors: Smith, A. David, Smith, Stephen M., de Jager, Celeste A., Whitbread, Philippa, Johnston, Carole, Agacinski, Grzegorz, Oulhaj, Abderrahim, Bradley, Kevin M., Jacoby, Robin, Refsum, Helga
Format: Journal Article
Language:English
Published: United States Public Library of Science 08.09.2010
Public Library of Science (PLoS)
Subjects:
Acids
Activities of daily living
Aged
Aged, 80 and over
Aging
Alzheimer's disease
Alzheimers disease
Anatomy & physiology
Atrophy
Brain
Brain - diagnostic imaging
Brain - drug effects
Brain - metabolism
Brain - pathology
Clinical trials
Cognition Disorders - diagnostic imaging
Cognition Disorders - drug therapy
Cognition Disorders - metabolism
Cognition Disorders - pathology
Cognitive ability
Consent
Cyanocobalamin
Dementia
Dementia disorders
Diet
Dietary supplements
Disease control
Drug dosages
Female
Folic acid
Geriatrics
Geriatrics/Dementia
Homocysteine
Homocysteine - blood
Homocysteine - metabolism
Humans
Impairment
Magnetic Resonance Imaging
Male
Medical treatment
Memory
Mental Health/Alzheimer Disease
Mental Health/Cognitive Neurology
Mental Health/Dementia
Neurodegenerative diseases
Neurological Disorders/Alzheimer Disease
Neurological Disorders/Cognitive Neurology and Dementia
Neurology
NMR
Nuclear magnetic resonance
Nutrition
Older people
Pharmacology
Physiology
Radiography
Radiology and Medical Imaging/Magnetic Resonance Imaging
Randomization
Risk factors
Skull
Supplementation
Treatment Outcome
Vitamin B
Vitamin B Complex - therapeutic use
Vitamin B12
Vitamin B6
Vitamins
ISSN:1932-6203, 1932-6203
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins. To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159). Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B(6) and B(12) in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B(12) (0.5 mg/d) and vitamin B(6) (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans. A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P =  0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 µmol/L was 53% lower in the active treatment group (P =  0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category. The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease. Controlled-Trials.com ISRCTN94410159.
AbstractList An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins. To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159). Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B.sub.6 and B.sub.12 in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B.sub.12 (0.5 mg/d) and vitamin B.sub.6 (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans. A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P = 0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 [micro]mol/L was 53% lower in the active treatment group (P = 0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category. The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease.
Background An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins. Objective To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159). Methods and Findings Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B.sub.6 and B.sub.12 in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B.sub.12 (0.5 mg/d) and vitamin B.sub.6 (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans. Results A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P = 0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 [micro]mol/L was 53% lower in the active treatment group (P = 0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category. Conclusions and Significance The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease. Trial Registration Controlled-Trials.com ISRCTN94410159
BackgroundAn increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins.ObjectiveTo determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159).Methods and findingsSingle-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B(6) and B(12) in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B(12) (0.5 mg/d) and vitamin B(6) (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans.ResultsA total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P =  0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 µmol/L was 53% lower in the active treatment group (P =  0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category.Conclusions and significanceThe accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease.Trial registrationControlled-Trials.com ISRCTN94410159.
Background An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins. Objective To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159). Methods and Findings Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B6 and B12 in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B12 (0.5 mg/d) and vitamin B6 (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans. Results A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63–0.90] in the active treatment group and 1.08% [0.94–1.22] in the placebo group (P = 0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 µmol/L was 53% lower in the active treatment group (P = 0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category. Conclusions and Significance The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease. Trial Registration Controlled-Trials.com ISRCTN94410159
An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins.BACKGROUNDAn increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins.To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159).OBJECTIVETo determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159).Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B(6) and B(12) in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B(12) (0.5 mg/d) and vitamin B(6) (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans.METHODS AND FINDINGSSingle-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B(6) and B(12) in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B(12) (0.5 mg/d) and vitamin B(6) (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans.A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P =  0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 µmol/L was 53% lower in the active treatment group (P =  0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category.RESULTSA total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P =  0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 µmol/L was 53% lower in the active treatment group (P =  0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category.The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease.CONCLUSIONS AND SIGNIFICANCEThe accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease.Controlled-Trials.com ISRCTN94410159.TRIAL REGISTRATIONControlled-Trials.com ISRCTN94410159.
An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins. To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159). Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B(6) and B(12) in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B(12) (0.5 mg/d) and vitamin B(6) (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans. A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P =  0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 µmol/L was 53% lower in the active treatment group (P =  0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category. The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease. Controlled-Trials.com ISRCTN94410159.
Background An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins. Objective To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159). Methods and Findings Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B6 and B12 in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B12 (0.5 mg/d) and vitamin B6 (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans. Results A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63–0.90] in the active treatment group and 1.08% [0.94–1.22] in the placebo group (P = 0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 µmol/L was 53% lower in the active treatment group (P = 0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category. Conclusions and Significance The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease. Trial Registration Controlled-Trials.com ISRCTN94410159
An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins. To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159). Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B6 and B12 in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B12 (0.5 mg/d) and vitamin B6 (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans. A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P=0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 kmol/L was 53% lower in the active treatment group (P=0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category. The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease. Controlled-Trials.com ISRCTN94410159
Audience Academic
Author de Jager, Celeste A.
Oulhaj, Abderrahim
Smith, Stephen M.
Jacoby, Robin
Refsum, Helga
Agacinski, Grzegorz
Johnston, Carole
Bradley, Kevin M.
Smith, A. David
Whitbread, Philippa
AuthorAffiliation 4 Department of Radiology and Nuclear Medicine, Oxford Radcliffe Hospitals NHS Trust, Oxford, United Kingdom
1 Oxford Project to Investigate Memory and Ageing (OPTIMA), University of Oxford, Oxford, United Kingdom
2 University Department of Pharmacology and Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, United Kingdom
3 Department of Clinical Neurology, Oxford Centre for Functional Magnetic Resonance Imaging of the Brain, University of Oxford, Oxford, United Kingdom
6 Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
5 University Department of Psychiatry, University of Oxford, Oxford, United Kingdom
Mental Health Research Institute of Victoria, Australia
AuthorAffiliation_xml – name: 3 Department of Clinical Neurology, Oxford Centre for Functional Magnetic Resonance Imaging of the Brain, University of Oxford, Oxford, United Kingdom
– name: 2 University Department of Pharmacology and Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, United Kingdom
– name: 6 Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
– name: 1 Oxford Project to Investigate Memory and Ageing (OPTIMA), University of Oxford, Oxford, United Kingdom
– name: 4 Department of Radiology and Nuclear Medicine, Oxford Radcliffe Hospitals NHS Trust, Oxford, United Kingdom
– name: 5 University Department of Psychiatry, University of Oxford, Oxford, United Kingdom
– name: Mental Health Research Institute of Victoria, Australia
Author_xml – sequence: 1
  givenname: A. David
  surname: Smith
  fullname: Smith, A. David
– sequence: 2
  givenname: Stephen M.
  surname: Smith
  fullname: Smith, Stephen M.
– sequence: 3
  givenname: Celeste A.
  surname: de Jager
  fullname: de Jager, Celeste A.
– sequence: 4
  givenname: Philippa
  surname: Whitbread
  fullname: Whitbread, Philippa
– sequence: 5
  givenname: Carole
  surname: Johnston
  fullname: Johnston, Carole
– sequence: 6
  givenname: Grzegorz
  surname: Agacinski
  fullname: Agacinski, Grzegorz
– sequence: 7
  givenname: Abderrahim
  surname: Oulhaj
  fullname: Oulhaj, Abderrahim
– sequence: 8
  givenname: Kevin M.
  surname: Bradley
  fullname: Bradley, Kevin M.
– sequence: 9
  givenname: Robin
  surname: Jacoby
  fullname: Jacoby, Robin
– sequence: 10
  givenname: Helga
  surname: Refsum
  fullname: Refsum, Helga
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20838622$$D View this record in MEDLINE/PubMed
BookMark eNqNk11vFCEUhiemxn7oPzBKYqLxYldgPoBemGwbtZvUNGlrbwkDzC4NAyuwretf8E_L2G3TbRo1czGHM895z_DC2S22nHe6KF4iOEYlQR8u_TI4YceLnB5DiDCuqifFDmIlHjUYllv34u1iN8ZLCOuSNs2zYhtDmiOMd4pfR773chWTNk6Pjv21DsbNQLsCB-DCJNEbF8GZ9dcRpLkGpyJp4DswkVJbHfJKgYMgjAOTFPxivgI5_GqsAod-5kwyVxpM-4Uwodcu7YNJVnDK9-anHhCXi6zN4Xkwwj4vnnbCRv1i_d4rvn3-dH54NDo--TI9nByPJKEsjQSVZctKomqoK6UFok3b1LTDSlBG2rqiSuSNqk6KTpO8UIRCplrZqhbSri73itc3ugvrI1_7GDnCDGNW1RXKxPSGUF5c8kUwvQgr7oXhfxI-zLgIyUirOUYN0iXEihJYaaUZga2gsGKsIYygodvHdbdl22slsw9B2A3RzS_OzPnMX3HMypoymAXerQWC_77UMfHexGy_FU77ZeSsrmpS5T3-kyR1jSiEJc7kmwfk4zasqZnIOzWu8_kH5aDJJxXJNwjSeug6foTKj9K9kfl2dibnNwrebxRkJukfaSaWMfLp2en_sycXm-zbe-xcC5vm0dtlMt7FTfDV_SO5O4vbschAdQPI4GMMurtDEOTD9N3axYfp4-vpy2X7D8pkHqGhfXbE2L8X_wZokTXF
CitedBy_id crossref_primary_10_3390_nu12113248
crossref_primary_10_1177_0962280217717761
crossref_primary_10_1111_nyas_13070
crossref_primary_10_1139_cjpp_2020_0215
crossref_primary_10_1016_j_nut_2014_06_016
crossref_primary_10_1016_S1474_4422_16_30128_4
crossref_primary_10_3390_nu8020068
crossref_primary_10_1134_S1819712416020069
crossref_primary_10_1371_journal_pone_0056927
crossref_primary_10_3390_nu7075266
crossref_primary_10_1111_nyas_13062
crossref_primary_10_7759_cureus_77860
crossref_primary_10_1016_j_bbagen_2016_06_018
crossref_primary_10_1016_j_mam_2016_11_003
crossref_primary_10_1016_j_biopha_2022_113337
crossref_primary_10_1155_2017_6083629
crossref_primary_10_1002_gps_2758
crossref_primary_10_1080_09637486_2019_1648387
crossref_primary_10_3390_nu8120803
crossref_primary_10_1111_acel_14255
crossref_primary_10_1002_trc2_12159
crossref_primary_10_3390_nu14020333
crossref_primary_10_1016_j_neurobiolaging_2019_02_001
crossref_primary_10_3390_ijms25179339
crossref_primary_10_1093_jn_nxy201
crossref_primary_10_1016_j_bcp_2013_11_009
crossref_primary_10_1016_j_neurobiolaging_2014_01_154
crossref_primary_10_1017_S0954422418000185
crossref_primary_10_1038_nrneurol_2010_195
crossref_primary_10_1186_alzrt105
crossref_primary_10_3390_nu16142199
crossref_primary_10_1016_j_biopsych_2018_12_018
crossref_primary_10_1080_13607863_2021_1875194
crossref_primary_10_1111_nhs_12315
crossref_primary_10_1186_s13195_020_00658_7
crossref_primary_10_3928_00989134_20140304_99
crossref_primary_10_1177_1099800415569506
crossref_primary_10_1212_CPJ_0000000000000890
crossref_primary_10_1016_j_arr_2024_102278
crossref_primary_10_1016_j_plefa_2019_04_001
crossref_primary_10_1016_j_nutres_2012_09_005
crossref_primary_10_2217_ahe_12_50
crossref_primary_10_1016_j_plipres_2025_101356
crossref_primary_10_3233_JAD_180879
crossref_primary_10_1016_j_nicl_2012_09_012
crossref_primary_10_1186_s12879_019_3742_8
crossref_primary_10_3389_fnagi_2018_00049
crossref_primary_10_1371_journal_pone_0156770
crossref_primary_10_1002_alz_13809
crossref_primary_10_1038_s41430_021_01057_3
crossref_primary_10_3390_nu16203567
crossref_primary_10_1016_S1474_4422_16_00062_4
crossref_primary_10_1016_j_parkreldis_2024_107208
crossref_primary_10_3389_fnins_2017_00596
crossref_primary_10_1007_s12603_017_0979_z
crossref_primary_10_1007_s10072_018_3473_4
crossref_primary_10_1080_10426507_2012_736104
crossref_primary_10_1055_a_1449_1786
crossref_primary_10_1017_S0954422415000141
crossref_primary_10_3389_fnins_2023_1214976
crossref_primary_10_2217_cpr_12_3
crossref_primary_10_3390_ijms20020319
crossref_primary_10_1038_ejcn_2014_177
crossref_primary_10_1016_j_brainres_2012_09_026
crossref_primary_10_1016_j_neurobiolaging_2014_01_013
crossref_primary_10_3389_fnagi_2023_1221768
crossref_primary_10_1016_j_clnesp_2023_04_023
crossref_primary_10_1016_j_dadm_2015_11_002
crossref_primary_10_1017_S0007114517003452
crossref_primary_10_3390_ijms232314924
crossref_primary_10_1038_aps_2015_20
crossref_primary_10_1017_S0029665114001554
crossref_primary_10_1194_jlr_R076331
crossref_primary_10_7759_cureus_63792
crossref_primary_10_1111_j_1471_4159_2011_07280_x
crossref_primary_10_1002_mds_28070
crossref_primary_10_1016_j_jalz_2011_11_008
crossref_primary_10_3390_nu13114059
crossref_primary_10_1016_j_psc_2012_12_001
crossref_primary_10_1016_j_clnu_2010_12_004
crossref_primary_10_1073_pnas_1301816110
crossref_primary_10_1177_0963721414565449
crossref_primary_10_1186_s12986_021_00630_8
crossref_primary_10_1017_S0007114517003464
crossref_primary_10_3233_JAD_220148
crossref_primary_10_1016_j_ejphar_2011_07_011
crossref_primary_10_1016_j_lfs_2021_119819
crossref_primary_10_3389_fnut_2022_1046726
crossref_primary_10_20960_nh_04394
crossref_primary_10_1016_j_mri_2015_10_026
crossref_primary_10_3390_nu10121860
crossref_primary_10_1016_j_exger_2017_10_008
crossref_primary_10_1212_WNL_0000000000001050
crossref_primary_10_1186_s13643_020_01378_7
crossref_primary_10_12968_bjon_2020_29_8_460
crossref_primary_10_1177_1559827619843465
crossref_primary_10_3390_biom10081119
crossref_primary_10_3233_JAD_150826
crossref_primary_10_1089_act_2012_18309
crossref_primary_10_1111_nbu_12250
crossref_primary_10_1002_alz_12871
crossref_primary_10_1016_S1474_4422_16_30074_6
crossref_primary_10_1192_apt_bp_110_008888
crossref_primary_10_1016_j_trci_2019_11_004
crossref_primary_10_1016_j_jff_2019_103511
crossref_primary_10_1186_s12877_021_02581_4
crossref_primary_10_1016_j_arr_2016_09_010
crossref_primary_10_3390_molecules28124824
crossref_primary_10_1016_j_parkreldis_2017_08_005
crossref_primary_10_3390_nu14235079
crossref_primary_10_1136_bmjopen_2018_023664
crossref_primary_10_1139_cjpp_2020_0224
crossref_primary_10_3389_fcell_2024_1294726
crossref_primary_10_1016_j_clinthera_2018_02_014
crossref_primary_10_1016_j_foodchem_2013_08_122
crossref_primary_10_1111_nure_12144
crossref_primary_10_3233_JAD_190249
crossref_primary_10_1016_j_clnu_2022_04_023
crossref_primary_10_1016_j_jchromb_2010_10_035
crossref_primary_10_3233_JAD_210137
crossref_primary_10_3390_ijms241813900
crossref_primary_10_1159_000363054
crossref_primary_10_1212_WNL_0000000000002121
crossref_primary_10_1055_a_2261_6118
crossref_primary_10_1007_s12603_016_0823_x
crossref_primary_10_1515_CCLM_2011_084
crossref_primary_10_1017_S0007114513001384
crossref_primary_10_1017_S0029665117004177
crossref_primary_10_1038_s41538_017_0002_4
crossref_primary_10_3945_ajcn_114_097808
crossref_primary_10_1056_NEJMc1108238
crossref_primary_10_1017_S1041610211000779
crossref_primary_10_1055_s_0042_1759580
crossref_primary_10_1016_j_tjpad_2025_100265
crossref_primary_10_1016_j_clnu_2019_11_005
crossref_primary_10_1093_nutrit_nux032
crossref_primary_10_1111_jhn_13080
crossref_primary_10_1007_s10048_024_00791_7
crossref_primary_10_1016_j_neuint_2024_105869
crossref_primary_10_1016_j_tifs_2021_01_023
crossref_primary_10_3389_fnagi_2024_1434943
crossref_primary_10_1002_mnfr_201801178
crossref_primary_10_1186_s40303_016_0018_8
crossref_primary_10_1002_14651858_CD011906_pub2
crossref_primary_10_1042_BJ20131568
crossref_primary_10_3390_neurolint17040047
crossref_primary_10_3390_nu15245116
crossref_primary_10_1007_s12603_014_0510_8
crossref_primary_10_1186_s40035_023_00370_0
crossref_primary_10_1124_dmd_114_061473
crossref_primary_10_3390_ph14121218
crossref_primary_10_1016_j_cgh_2022_04_035
crossref_primary_10_1016_j_jns_2013_06_023
crossref_primary_10_3390_biomedicines11020335
crossref_primary_10_3945_an_113_004283
crossref_primary_10_1097_YCO_0000000000000605
crossref_primary_10_3233_JAD_170796
crossref_primary_10_3233_JAD_200534
crossref_primary_10_1186_s11556_019_0217_2
crossref_primary_10_1002_alz_13884
crossref_primary_10_1017_S0007114518002945
crossref_primary_10_3233_JAD_160667
crossref_primary_10_1186_s12877_021_02253_3
crossref_primary_10_7759_cureus_53711
crossref_primary_10_3390_pr6080097
crossref_primary_10_1017_S1368980014000974
crossref_primary_10_1177_09564624231218762
crossref_primary_10_1515_cclm_2012_0673
crossref_primary_10_4103_1673_5374_211183
crossref_primary_10_1177_2380084416673963
crossref_primary_10_1111_febs_13912
crossref_primary_10_1177_2155179017722280
crossref_primary_10_1177_0260106020940116
crossref_primary_10_1007_s12640_019_00119_6
crossref_primary_10_1111_jcpp_12817
crossref_primary_10_1016_j_neurobiolaging_2012_10_022
crossref_primary_10_3233_JAD_180366
crossref_primary_10_1016_j_advnut_2023_04_003
crossref_primary_10_1002_alz_70235
crossref_primary_10_1007_s00018_011_0861_9
crossref_primary_10_1016_j_arcmed_2012_10_010
crossref_primary_10_3390_nu14214564
crossref_primary_10_3389_fnagi_2018_00350
crossref_primary_10_1016_j_jns_2019_07_015
crossref_primary_10_3390_nu17152545
crossref_primary_10_3389_fnagi_2016_00288
crossref_primary_10_3390_medicina58081025
crossref_primary_10_3233_JAD_220685
crossref_primary_10_1038_s41598_019_47282_6
crossref_primary_10_1080_1028415X_2017_1395550
crossref_primary_10_1186_s13195_020_00683_6
crossref_primary_10_3233_JAD_181148
crossref_primary_10_1038_s41531_022_00375_y
crossref_primary_10_1002_alz_70521
crossref_primary_10_1016_j_jnutbio_2023_109536
crossref_primary_10_1016_j_mri_2015_02_012
crossref_primary_10_1080_10408363_2021_1885339
crossref_primary_10_1371_journal_pone_0033345
crossref_primary_10_2169_internalmedicine_5966_25
crossref_primary_10_12968_bjon_2015_24_12_624
crossref_primary_10_4103_2277_8632_102435
crossref_primary_10_1515_pteridines_2019_0013
crossref_primary_10_1007_s00221_012_3392_1
crossref_primary_10_1017_S0007114512004771
crossref_primary_10_1038_s41392_022_01251_0
crossref_primary_10_3389_fnut_2019_00049
crossref_primary_10_1007_s40120_022_00416_x
crossref_primary_10_1016_j_bbr_2015_01_016
crossref_primary_10_1093_epirev_mxs003
crossref_primary_10_12956_tchd_1094163
crossref_primary_10_1016_S1474_4422_18_30338_7
crossref_primary_10_1002_hsr2_1500
crossref_primary_10_1016_j_clnu_2023_10_025
crossref_primary_10_1007_s13668_020_00333_1
crossref_primary_10_1016_S1474_4422_15_00153_2
crossref_primary_10_3233_JAD_215085
crossref_primary_10_1136_bmjnph_2020_000209
crossref_primary_10_1177_1357633X12473904
crossref_primary_10_3233_JAD_150304
crossref_primary_10_3233_JAD_150301
crossref_primary_10_1007_s00394_017_1604_y
crossref_primary_10_1007_s13668_020_00311_7
crossref_primary_10_1177_0004563212473279
crossref_primary_10_1007_s00234_013_1306_y
crossref_primary_10_3390_biom11101546
crossref_primary_10_2217_nmt_12_24
crossref_primary_10_3233_JAD_181007
crossref_primary_10_1016_j_neuroimage_2015_06_094
crossref_primary_10_3233_JAD_230231
crossref_primary_10_1017_S0317167100012129
crossref_primary_10_3233_JAD_150777
crossref_primary_10_2217_nmt_11_61
crossref_primary_10_1212_WNL_0000000000200300
crossref_primary_10_3389_fnagi_2023_1242853
crossref_primary_10_1016_j_preteyeres_2011_01_001
crossref_primary_10_1096_fj_11_201558
crossref_primary_10_1016_j_tifs_2014_07_012
crossref_primary_10_1016_j_nutres_2022_10_008
crossref_primary_10_1016_j_jamda_2017_07_010
crossref_primary_10_1007_s12603_015_0539_3
crossref_primary_10_1002_biof_1006
crossref_primary_10_1007_s11011_018_0268_5
crossref_primary_10_1007_s11239_012_0856_x
crossref_primary_10_1212_WNL_0b013e3182315a33
crossref_primary_10_1007_s00726_011_1207_5
crossref_primary_10_3389_fnagi_2022_1014559
crossref_primary_10_1007_s12603_021_1708_1
crossref_primary_10_2217_nmt_2015_0008
crossref_primary_10_1016_j_exger_2016_05_002
crossref_primary_10_1017_S0029665117000404
crossref_primary_10_1177_1533317512442998
crossref_primary_10_1007_s00406_015_0583_3
crossref_primary_10_1111_bjh_12959
crossref_primary_10_1017_S0007114512004175
crossref_primary_10_1017_S0007114522001283
crossref_primary_10_3233_JAD_160241
crossref_primary_10_1093_ajcn_nqab013
crossref_primary_10_1136_bmjopen_2018_026564
crossref_primary_10_1002_mds_25798
crossref_primary_10_1016_j_cmet_2020_09_002
crossref_primary_10_3390_nu16223929
crossref_primary_10_3390_nu11010019
crossref_primary_10_1016_j_trci_2016_07_002
crossref_primary_10_1186_s12916_014_0218_y
crossref_primary_10_1007_s12011_015_0568_0
crossref_primary_10_3233_JAD_160393
crossref_primary_10_3945_ajcn_114_103283
crossref_primary_10_1093_nutrit_nuv107
crossref_primary_10_1038_nrd3869
crossref_primary_10_1016_j_brainres_2013_01_050
crossref_primary_10_3109_00365513_2012_657230
crossref_primary_10_1016_j_jpsychires_2023_01_045
crossref_primary_10_1016_j_bbadis_2015_11_015
crossref_primary_10_1016_j_parkreldis_2023_105357
crossref_primary_10_1007_s12603_020_1489_y
crossref_primary_10_1007_s13311_021_01170_y
crossref_primary_10_1016_j_biochi_2013_02_008
crossref_primary_10_2196_20995
crossref_primary_10_1097_WAD_0b013e31825cbc4b
crossref_primary_10_3945_ajcn_112_034785
crossref_primary_10_1016_j_nut_2013_01_024
crossref_primary_10_3390_nu14071494
crossref_primary_10_3233_JAD_220410
crossref_primary_10_1146_annurev_nutr_071715_050947
crossref_primary_10_1007_s00018_013_1369_2
crossref_primary_10_1177_03795721241228060
crossref_primary_10_3390_nu9010008
crossref_primary_10_1186_s12916_025_04276_8
crossref_primary_10_1186_s13195_014_0087_9
crossref_primary_10_1186_s13195_019_0506_z
crossref_primary_10_1186_s13195_019_0528_6
crossref_primary_10_1017_S0029665112002819
crossref_primary_10_1038_nrdp_2017_40
crossref_primary_10_1017_S0029665123002707
crossref_primary_10_1016_j_neurobiolaging_2012_01_092
crossref_primary_10_1016_j_gerinurse_2025_03_038
crossref_primary_10_1002_mnfr_201200477
crossref_primary_10_1007_s12603_015_0595_8
crossref_primary_10_3945_ajcn_115_116970
crossref_primary_10_1159_000338610
crossref_primary_10_1007_s40263_015_0256_9
crossref_primary_10_3390_nu16183114
crossref_primary_10_3390_nu8100665
crossref_primary_10_1097_MD_0000000000004535
crossref_primary_10_1016_j_neurobiolaging_2013_11_011
crossref_primary_10_1097_MD_0000000000038680
crossref_primary_10_1016_j_nupar_2011_09_004
crossref_primary_10_3233_JAD_201096
crossref_primary_10_3945_ajcn_115_114322
crossref_primary_10_1007_s12291_017_0646_5
crossref_primary_10_1111_joim_13279
crossref_primary_10_1016_j_jamda_2017_05_008
crossref_primary_10_1016_j_parkreldis_2020_03_009
crossref_primary_10_1093_toxres_tfab065
crossref_primary_10_1016_j_pmr_2011_11_001
crossref_primary_10_1093_eurheartj_ehr467
crossref_primary_10_1111_joim_12191
crossref_primary_10_3390_ani13193056
crossref_primary_10_1002_mds_25352
crossref_primary_10_1016_j_neubiorev_2020_12_022
crossref_primary_10_1089_act_2011_17104
crossref_primary_10_1159_000531849
crossref_primary_10_1016_j_arr_2018_10_010
crossref_primary_10_1053_j_jrn_2011_07_009
crossref_primary_10_1093_nutrit_nuv022
crossref_primary_10_1177_0271678X221122644
crossref_primary_10_29254_2077_4214_2022_2_2_165_109_123
crossref_primary_10_1177_2326409817701471
crossref_primary_10_1002_alz_14376
crossref_primary_10_3389_fnins_2021_778123
crossref_primary_10_1016_j_jnutbio_2013_01_002
crossref_primary_10_1016_j_ibneur_2025_03_007
crossref_primary_10_3945_jn_114_206599
crossref_primary_10_1017_S0029665119000661
crossref_primary_10_1371_journal_pone_0136468
crossref_primary_10_3389_fpubh_2025_1494916
crossref_primary_10_3390_nu15183911
crossref_primary_10_3945_ajcn_117_157834
crossref_primary_10_1007_s00394_013_0526_6
crossref_primary_10_1007_s13668_017_0199_5
crossref_primary_10_3390_biom14101213
crossref_primary_10_3390_nu16010135
crossref_primary_10_1016_j_thromres_2024_109096
crossref_primary_10_3390_nu5125031
crossref_primary_10_1016_j_jacc_2017_01_022
crossref_primary_10_1016_j_phrp_2010_12_006
crossref_primary_10_3945_ajcn_114_098467
crossref_primary_10_14283_jarlife_2023_7
crossref_primary_10_1080_09637486_2017_1320536
crossref_primary_10_3390_md16090313
crossref_primary_10_1007_s40495_016_0046_1
crossref_primary_10_1007_s12603_015_0660_3
crossref_primary_10_1016_j_nutres_2015_10_003
crossref_primary_10_1007_s12603_012_0051_y
crossref_primary_10_1016_j_jnutbio_2012_11_001
crossref_primary_10_1007_s10549_018_4805_z
crossref_primary_10_1007_s12035_024_03995_y
crossref_primary_10_1002_trc2_12202
crossref_primary_10_1179_0001551213Z_0000000006
crossref_primary_10_3389_fmed_2025_1522531
crossref_primary_10_3390_nu8110725
crossref_primary_10_1080_10408398_2018_1481012
crossref_primary_10_1177_1759091419865788
crossref_primary_10_1111_j_1758_5872_2011_00137_x
crossref_primary_10_1007_s11011_021_00712_9
crossref_primary_10_1016_j_cger_2015_04_008
crossref_primary_10_1007_s12640_021_00429_8
crossref_primary_10_1007_s11357_025_01567_z
crossref_primary_10_1016_j_neubiorev_2014_08_006
crossref_primary_10_20960_nh_05723
crossref_primary_10_1111_cns_14131
crossref_primary_10_1002_trc2_12314
crossref_primary_10_3390_jcm11020394
crossref_primary_10_3390_nu8120761
crossref_primary_10_1007_s11011_025_01578_x
crossref_primary_10_1016_j_neurobiolaging_2014_03_040
crossref_primary_10_3390_ijms26104929
crossref_primary_10_1016_j_aimed_2015_11_002
crossref_primary_10_1016_j_clnu_2016_10_018
crossref_primary_10_1371_journal_pone_0085632
crossref_primary_10_1093_nutrit_nuab057
crossref_primary_10_1007_s40266_019_00649_w
crossref_primary_10_3390_ijms26031333
crossref_primary_10_3389_fnut_2023_1179807
crossref_primary_10_1159_000547151
crossref_primary_10_3389_fnut_2024_1459638
crossref_primary_10_1002_ana_27200
crossref_primary_10_1016_j_clnu_2015_03_023
crossref_primary_10_1096_fj_201600915R
crossref_primary_10_3390_brainsci9120370
crossref_primary_10_1016_j_neubiorev_2018_10_022
crossref_primary_10_1016_j_neurobiolaging_2014_03_033
crossref_primary_10_1017_S0029665116000033
crossref_primary_10_1111_jhn_12566
crossref_primary_10_3389_fnut_2025_1551375
crossref_primary_10_1111_jdi_13875
crossref_primary_10_3945_an_117_015610
crossref_primary_10_1016_j_arr_2022_101777
crossref_primary_10_1007_s12603_015_0576_y
crossref_primary_10_1017_S0007114520000951
crossref_primary_10_1038_s41598_021_01059_y
crossref_primary_10_3390_healthcare6030082
crossref_primary_10_1093_nutrit_nuaa091
crossref_primary_10_1039_D5RA02268A
crossref_primary_10_1515_jpm_2014_0346
crossref_primary_10_1016_j_chroma_2013_09_027
crossref_primary_10_18261_ntfe_17_3_2
crossref_primary_10_3390_nu14173535
crossref_primary_10_1212_WNL_0000000000200185
crossref_primary_10_1371_journal_pone_0187364
crossref_primary_10_3233_JAD_201481
crossref_primary_10_1007_s13311_022_01276_x
crossref_primary_10_1111_ajag_12913
crossref_primary_10_1017_S0029665112003023
crossref_primary_10_1080_1028415X_2020_1826762
crossref_primary_10_4061_2011_501862
crossref_primary_10_3390_nu13124396
crossref_primary_10_1017_S0029665111003296
crossref_primary_10_1016_S1474_4422_17_30332_0
crossref_primary_10_1177_13872877251350297
crossref_primary_10_1007_s00394_013_0561_3
crossref_primary_10_1080_21678421_2020_1743470
crossref_primary_10_1093_hmg_ddab246
crossref_primary_10_1016_j_jamda_2018_10_017
crossref_primary_10_1016_S0140_6736_10_61994_0
crossref_primary_10_3390_jfmk2030030
crossref_primary_10_3945_ajcn_113_076349
crossref_primary_10_2147_NDT_S460938
crossref_primary_10_1055_a_1210_5030
crossref_primary_10_1002_path_5254
crossref_primary_10_3390_nu12103138
crossref_primary_10_1016_j_arr_2020_101079
crossref_primary_10_1371_journal_pone_0146797
crossref_primary_10_1007_s12603_015_0531_y
crossref_primary_10_1007_s12013_014_0246_4
crossref_primary_10_1139_apnm_2022_0111
crossref_primary_10_1007_s13668_014_0111_5
crossref_primary_10_1016_j_bmcl_2011_08_123
crossref_primary_10_2478_FON_2019_0038
crossref_primary_10_3390_app151810191
crossref_primary_10_3390_biomedicines10112741
crossref_primary_10_1038_srep37486
crossref_primary_10_1016_j_nutres_2017_09_008
crossref_primary_10_1186_s12986_025_00981_6
crossref_primary_10_3390_nu13092966
crossref_primary_10_1007_s12035_017_0493_7
crossref_primary_10_1002_ana_26673
crossref_primary_10_3390_nu9010053
crossref_primary_10_1016_j_bbr_2015_06_004
crossref_primary_10_1038_jcbfm_2015_68
crossref_primary_10_1136_bmjopen_2016_011247
crossref_primary_10_1371_journal_pone_0031501
crossref_primary_10_1016_j_tem_2013_01_010
crossref_primary_10_1007_s13670_018_0241_5
crossref_primary_10_1111_bcp_12058
crossref_primary_10_3390_biom12010129
crossref_primary_10_1016_S1474_4422_10_70304_5
crossref_primary_10_1097_MOG_0b013e3283505852
crossref_primary_10_1080_13554794_2025_2489928
crossref_primary_10_1111_j_1365_2796_2011_02485_x
crossref_primary_10_1016_j_exger_2022_112045
crossref_primary_10_1016_j_jalz_2013_05_1771
Cites_doi 10.1259/bjr.75.894.750506
10.2174/156720509788929273
10.1073/pnas.082107399
10.1001/archneur.1993.00540060039014
10.1007/s00125-003-1235-0
10.1001/jama.300.15.1774
10.1001/archneurol.2009.266
10.1093/ajcn/82.4.806
10.1097/01.psy.0000237779.56500.af
10.1161/01.HYP.32.3.404
10.3233/JAD-2006-9404
10.1001/archneur.65.5.642
10.1212/01.WNL.0000110315.26026.EF
10.1373/clinchem.2007.100214
10.1093/brain/awg006
10.1002/(SICI)1099-1166(199804)13:4<235::AID-GPS761>3.0.CO;2-8
10.1212/01.wnl.0000280577.43413.d9
10.1016/S1474-4422(03)00262-X
10.1136/jnnp.2007.122028
10.1016/S0140-6736(07)60109-3
10.1111/j.1532-5415.2008.01684.x
10.1093/ajcn/80.3.641
10.1212/WNL.58.10.1539
10.1093/jn/136.6.1731S
10.1373/clinchem.2003.021634
10.1212/01.wnl.0000313380.89894.54
10.1523/JNEUROSCI.23-08-03295.2003
10.1212/WNL.39.9.1159
10.1002/gps.830
10.1016/j.brainres.2008.01.030
10.1177/15648265080292S119
10.1212/01.WNL.0000161871.83614.BB
10.1212/WNL.52.8.1687
10.1080/07315724.2007.10719611
10.1148/radiol.2482070938
10.1212/01.wnl.0000325581.26991.f2
10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.0.CO;2-I
10.7326/0003-4819-148-6-200803180-00005
10.1093/ageing/31.6.440
10.1001/archneur.55.11.1449
10.1212/01.wnl.0000180958.22678.91
10.1006/nimg.2002.1040
ContentType Journal Article
Copyright COPYRIGHT 2010 Public Library of Science
2010 Smith et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Smith et al. 2010
Copyright_xml – notice: COPYRIGHT 2010 Public Library of Science
– notice: 2010 Smith et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Smith et al. 2010
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7QG
7QL
7QO
7RV
7SN
7SS
7T5
7TG
7TM
7U9
7X2
7X7
7XB
88E
8AO
8C1
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AEUYN
AFKRA
ARAPS
ATCPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB.
KB0
KL.
L6V
LK8
M0K
M0S
M1P
M7N
M7P
M7S
NAPCQ
P5Z
P62
P64
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PTHSS
PYCSY
RC3
7X8
7TK
5PM
DOA
DOI 10.1371/journal.pone.0012244
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale in Context : Opposing Viewpoints
Gale In Context: Science
ProQuest Central (Corporate)
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Nursing & Allied Health Database
Ecology Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Agricultural Science Collection
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Computer Science Collection
Agricultural & Environmental Science Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Materials Science Database
Nursing & Allied Health Database (Alumni Edition)
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest Engineering Collection
Biological Sciences
Agriculture Science Database
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Engineering Database
Nursing & Allied Health Premium
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
Environmental Science Database
Materials Science Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection
Environmental Science Collection
Genetics Abstracts
MEDLINE - Academic
Neurosciences Abstracts
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Agricultural Science Database
Publicly Available Content Database
ProQuest Central Student
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Meteorological & Geoastrophysical Abstracts
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Advanced Technologies & Aerospace Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Agricultural Science Collection
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Science Collection
Entomology Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
ProQuest Engineering Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Agricultural & Environmental Science Collection
AIDS and Cancer Research Abstracts
Materials Science Database
ProQuest Materials Science Collection
ProQuest Public Health
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Animal Behavior Abstracts
Materials Science & Engineering Collection
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
Neurosciences Abstracts
DatabaseTitleList




Agricultural Science Database
MEDLINE - Academic

MEDLINE

Neurosciences Abstracts
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: ProQuest Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Anatomy & Physiology
DocumentTitleAlternate Homocysteine and Brain Atrophy
EISSN 1932-6203
ExternalDocumentID 1292294541
oai_doaj_org_article_2161e302d8704ede970ba80499679715
PMC2935890
2898048441
A473860850
20838622
10_1371_journal_pone_0012244
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Medical Research Council
  grantid: G0700399
GroupedDBID ---
123
29O
2WC
53G
5VS
7RV
7X2
7X7
7XC
88E
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAUCC
AAWOE
AAYXX
ABDBF
ABIVO
ABJCF
ABUWG
ACCTH
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
AEAQA
AENEX
AEUYN
AFFHD
AFKRA
AFPKN
AFRAH
AHMBA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
APEBS
ARAPS
ATCPS
BAWUL
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
D1I
D1J
D1K
DIK
DU5
E3Z
EAP
EAS
EBD
EMOBN
ESX
EX3
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IEA
IGS
IHR
IHW
INH
INR
IOV
IPNFZ
IPY
ISE
ISR
ITC
K6-
KB.
KQ8
L6V
LK5
LK8
M0K
M1P
M48
M7P
M7R
M7S
M~E
NAPCQ
O5R
O5S
OK1
OVT
P2P
P62
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PTHSS
PYCSY
RIG
RNS
RPM
SV3
TR2
UKHRP
WOQ
WOW
~02
~KM
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
BBORY
3V.
7QG
7QL
7QO
7SN
7SS
7T5
7TG
7TM
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
KL.
M7N
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
7X8
ESTFP
7TK
5PM
-
02
AAPBV
ABPTK
ADACO
BBAFP
KM
ID FETCH-LOGICAL-c789t-a8c3b937d50e4dea186b658f2da897b548da538dfcafe78dad7809dbcbdb08f53
IEDL.DBID M7P
ISICitedReferencesCount 544
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000281687100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1932-6203
IngestDate Thu Nov 25 14:37:23 EST 2021
Fri Oct 03 12:53:17 EDT 2025
Tue Nov 04 01:51:30 EST 2025
Sun Nov 23 09:46:11 EST 2025
Sun Nov 09 14:00:14 EST 2025
Sat Nov 29 14:56:20 EST 2025
Sat Nov 29 13:12:34 EST 2025
Sat Nov 29 10:26:14 EST 2025
Wed Nov 26 10:26:11 EST 2025
Wed Nov 26 10:41:03 EST 2025
Thu May 22 21:20:41 EDT 2025
Mon Jul 21 06:01:18 EDT 2025
Sat Nov 29 02:56:08 EST 2025
Tue Nov 18 22:33:07 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c789t-a8c3b937d50e4dea186b658f2da897b548da538dfcafe78dad7809dbcbdb08f53
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ObjectType-Feature-1
Conceived and designed the experiments: ADS CAdJ KMB RJ HR. Performed the experiments: SMS CAdJ PW CJ KMB RJ. Analyzed the data: ADS SMS CAdJ PW CJ GA AO HR. Contributed reagents/materials/analysis tools: CJ GA AO KMB RJ. Wrote the paper: ADS HR. Critically reviewed the manuscript: ADS SMS CAdJ PW CJ GA KMB RJ HR. Critically reviewed the manuscript, notably the statistics: AO.
OpenAccessLink https://www.proquest.com/docview/1292294541?pq-origsite=%requestingapplication%
PMID 20838622
PQID 1292294541
PQPubID 1436336
PageCount e12244
ParticipantIDs plos_journals_1292294541
doaj_primary_oai_doaj_org_article_2161e302d8704ede970ba80499679715
pubmedcentral_primary_oai_pubmedcentral_nih_gov_2935890
proquest_miscellaneous_954574780
proquest_miscellaneous_755180032
proquest_journals_1292294541
gale_infotracmisc_A473860850
gale_infotracacademiconefile_A473860850
gale_incontextgauss_ISR_A473860850
gale_incontextgauss_IOV_A473860850
gale_healthsolutions_A473860850
pubmed_primary_20838622
crossref_primary_10_1371_journal_pone_0012244
crossref_citationtrail_10_1371_journal_pone_0012244
PublicationCentury 2000
PublicationDate 2010-09-08
PublicationDateYYYYMMDD 2010-09-08
PublicationDate_xml – month: 09
  year: 2010
  text: 2010-09-08
  day: 08
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco
– name: San Francisco, USA
PublicationTitle PloS one
PublicationTitleAlternate PLoS One
PublicationYear 2010
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References T den Heijer (ref19) 2003; 126
S Seshadri (ref14) 2006; 9
CA De Jager (ref28) 2003; 18
NE Carlson (ref9) 2008; 70
PS Aisen (ref45) 2008; 300
DE Zylberstein (ref16) 2009
H Refsum (ref22) 2004; 50
MF Folstein (ref30) 1975; 12
C Enzinger (ref34) 2005; 64
JD Sluimer (ref8) 2008; 248
SL Risacher (ref11) 2009; 6
PS Aisen (ref43) 2008; 70
SM Smith (ref31) 2002; 17
AD Smith (ref4) 2002; 99
A McCaddon (ref13) 1998; 13
PS Sachdev (ref18) 2002; 58
BL Plassman (ref41) 2008; 148
A Vogiatzoglou (ref36) 2008; 71
R Clarke (ref12) 1998; 55
KJ Anstey (ref35) 2006; 68
(ref23) 2005; 82
JC Morris (ref29) 1989; 39
NC Fox (ref2) 1999; 52
H Refsum (ref37) 2006; 136
KM Bradley (ref3) 2002; 75
CR Jack Jr (ref7) 2005; 65
M Roth (ref25) 1988
AD Smith (ref15) 2008; 29
JH Williams (ref17) 2002; 31
T Den Heijer (ref33) 2003; 46
C DeCarli (ref42) 2003; 2
RC Petersen (ref24) 2009; 66
RJ Killiany (ref6) 2000; 47
ML Ries (ref10) 2008; 56
S Seshadri (ref21) 2008; 65
O Bleie (ref38) 2004; 80
J Brandt (ref27) 1993; 50
LK Yang (ref20) 2007; 26
SM Resnick (ref1) 2003; 23
KI Erickson (ref39) 2008; 1199
CR Jack Jr (ref5) 2004; 62
I Skoog (ref32) 1998; 32
CM Pfeiffer (ref40) 2008; 54
J Durga (ref44) 2007; 369
C Wedderburn (ref26) 2008; 79
References_xml – volume: 75
  start-page: 506
  year: 2002
  ident: ref3
  article-title: Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease.
  publication-title: Br J Radiol
  doi: 10.1259/bjr.75.894.750506
– volume: 6
  start-page: 347
  year: 2009
  ident: ref11
  article-title: Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.
  publication-title: Curr Alzheimer Res
  doi: 10.2174/156720509788929273
– volume: 99
  start-page: 4135
  year: 2002
  ident: ref4
  article-title: Imaging the progression of Alzheimer pathology through the brain.
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.082107399
– volume: 50
  start-page: 599
  year: 1993
  ident: ref27
  article-title: Hereditary influences on cognitive functioning in older men - a study of 4000 twin pairs.
  publication-title: Arch Neurol
  doi: 10.1001/archneur.1993.00540060039014
– volume: 46
  start-page: 1604
  year: 2003
  ident: ref33
  article-title: Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI.
  publication-title: Diabetologia
  doi: 10.1007/s00125-003-1235-0
– volume: 300
  start-page: 1774
  year: 2008
  ident: ref45
  article-title: High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.
  publication-title: Jama
  doi: 10.1001/jama.300.15.1774
– volume: 66
  start-page: 1447
  year: 2009
  ident: ref24
  article-title: Mild cognitive impairment: ten years later.
  publication-title: Arch Neurol
  doi: 10.1001/archneurol.2009.266
– volume: 82
  start-page: 806
  year: 2005
  ident: ref23
  article-title: Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials.
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/82.4.806
– volume: 68
  start-page: 778
  year: 2006
  ident: ref35
  article-title: Weekly alcohol consumption, brain atrophy, and white matter hyperintensities in a community-based sample aged 60 to 64 years.
  publication-title: Psychosom Med
  doi: 10.1097/01.psy.0000237779.56500.af
– year: 1988
  ident: ref25
  article-title: CAMDEX: The Cambridge examination for mental disorders of the elderly.
– volume: 12
  start-page: 189
  year: 1975
  ident: ref30
  article-title: Mini-mental state: a practical method of grading the cognitive state of patients for the clinician.
  publication-title: J Psychiatr Res
– volume: 32
  start-page: 404
  year: 1998
  ident: ref32
  article-title: A population-based study on blood pressure and brain atrophy in 85-year-olds.
  publication-title: Hypertension
  doi: 10.1161/01.HYP.32.3.404
– volume: 9
  start-page: 393
  year: 2006
  ident: ref14
  article-title: Elevated plasma homocysteine levels: Risk factor or risk marker for the development of dementia and Alzheimer's disease?
  publication-title: J Alzheimers Dis
  doi: 10.3233/JAD-2006-9404
– volume: 65
  start-page: 642
  year: 2008
  ident: ref21
  article-title: Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study.
  publication-title: Arch Neurol
  doi: 10.1001/archneur.65.5.642
– year: 2009
  ident: ref16
  article-title: Midlife homocysteine and late-life dementia in women.
– volume: 62
  start-page: 591
  year: 2004
  ident: ref5
  article-title: Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000110315.26026.EF
– volume: 54
  start-page: 801
  year: 2008
  ident: ref40
  article-title: Trends in circulating concentrations of total homocysteine among US adolescents and adults: findings from the 1991-1994 and 1999-2004 National Health and Nutrition Examination Surveys.
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2007.100214
– volume: 126
  start-page: 170
  year: 2003
  ident: ref19
  article-title: Homocysteine and brain atrophy on MRI of non-demented elderly.
  publication-title: Brain
  doi: 10.1093/brain/awg006
– volume: 13
  start-page: 235
  year: 1998
  ident: ref13
  article-title: Total serum homocysteine in senile dementia of Alzheimer type.
  publication-title: Int J Geriatr Psychiatry
  doi: 10.1002/(SICI)1099-1166(199804)13:4<235::AID-GPS761>3.0.CO;2-8
– volume: 70
  start-page: 828
  year: 2008
  ident: ref9
  article-title: Trajectories of brain loss in aging and the development of cognitive impairment.
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000280577.43413.d9
– volume: 2
  start-page: 15
  year: 2003
  ident: ref42
  article-title: Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment.
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(03)00262-X
– volume: 79
  start-page: 500
  year: 2008
  ident: ref26
  article-title: The utility of the Cambridge Behavioural Inventory in neurodegenerative disease.
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.2007.122028
– volume: 369
  start-page: 208
  year: 2007
  ident: ref44
  article-title: Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial.
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)60109-3
– volume: 56
  start-page: 920
  year: 2008
  ident: ref10
  article-title: Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review.
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.2008.01684.x
– volume: 80
  start-page: 641
  year: 2004
  ident: ref38
  article-title: Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention.
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/80.3.641
– volume: 58
  start-page: 1539
  year: 2002
  ident: ref18
  article-title: Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals.
  publication-title: Neurology
  doi: 10.1212/WNL.58.10.1539
– volume: 136
  start-page: 1731S
  year: 2006
  ident: ref37
  article-title: The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease.
  publication-title: J Nutr
  doi: 10.1093/jn/136.6.1731S
– volume: 50
  start-page: 3
  year: 2004
  ident: ref22
  article-title: Facts and recommendations about total homocysteine determinations: an expert opinion.
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2003.021634
– volume: 70
  start-page: 2020
  year: 2008
  ident: ref43
  article-title: Treatment for MCI: Is the evidence sufficient?
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000313380.89894.54
– volume: 23
  start-page: 3295
  year: 2003
  ident: ref1
  article-title: Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain.
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.23-08-03295.2003
– volume: 39
  start-page: 1159
  year: 1989
  ident: ref29
  article-title: The Consortium to Establish a Registry for Alzheimers Disease (CERAD). Part 1.Clinical and Neuropsychological Assessment of Alzheimers Disease.
  publication-title: Neurology
  doi: 10.1212/WNL.39.9.1159
– volume: 18
  start-page: 318
  year: 2003
  ident: ref28
  article-title: Utility of TICS-m for the assessment of cognitive function in older adults.
  publication-title: Int J Geriatr Psychiatry
  doi: 10.1002/gps.830
– volume: 1199
  start-page: 20
  year: 2008
  ident: ref39
  article-title: Greater intake of vitamins B6 and B12 spares gray matter in healthy elderly: A voxel-based morphometry study.
  publication-title: Brain Res
  doi: 10.1016/j.brainres.2008.01.030
– volume: 29
  start-page: S143
  year: 2008
  ident: ref15
  article-title: The worldwide challenge of the dementias: A role for B vitamins and homocysteine?
  publication-title: Food Nutr Bull
  doi: 10.1177/15648265080292S119
– volume: 64
  start-page: 1704
  year: 2005
  ident: ref34
  article-title: Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects.
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000161871.83614.BB
– volume: 52
  start-page: 1687
  year: 1999
  ident: ref2
  article-title: Correlation between rates of brain atrophy and cognitive decline in AD.
  publication-title: Neurology
  doi: 10.1212/WNL.52.8.1687
– volume: 26
  start-page: 272
  year: 2007
  ident: ref20
  article-title: Correlations between folate, B12, homocysteine levels, and radiological markers of neuropathology in elderly post-stroke patients.
  publication-title: J Am Coll Nutr
  doi: 10.1080/07315724.2007.10719611
– volume: 248
  start-page: 590
  year: 2008
  ident: ref8
  article-title: Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients.
  publication-title: Radiology
  doi: 10.1148/radiol.2482070938
– volume: 71
  start-page: 826
  year: 2008
  ident: ref36
  article-title: Vitamin B12 status and rate of brain volume loss in community-dwelling elderly.
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000325581.26991.f2
– volume: 47
  start-page: 430
  year: 2000
  ident: ref6
  article-title: Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.
  publication-title: Ann Neurol
  doi: 10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.0.CO;2-I
– volume: 148
  start-page: 427
  year: 2008
  ident: ref41
  article-title: Prevalence of cognitive impairment without dementia in the United States.
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-148-6-200803180-00005
– volume: 31
  start-page: 440
  year: 2002
  ident: ref17
  article-title: Minimal hippocampal width relates to plasma homocysteine in community-dwelling older people.
  publication-title: Age Ageing
  doi: 10.1093/ageing/31.6.440
– volume: 55
  start-page: 1449
  year: 1998
  ident: ref12
  article-title: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease.
  publication-title: Arch Neurol
  doi: 10.1001/archneur.55.11.1449
– volume: 65
  start-page: 1227
  year: 2005
  ident: ref7
  article-title: Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000180958.22678.91
– volume: 17
  start-page: 479
  year: 2002
  ident: ref31
  article-title: Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.
  publication-title: Neuroimage
  doi: 10.1006/nimg.2002.1040
SSID ssj0053866
Score 2.5493238
Snippet An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor...
Background An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a...
BackgroundAn increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk...
Background An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a...
SourceID plos
doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e12244
SubjectTerms Acids
Activities of daily living
Aged
Aged, 80 and over
Aging
Alzheimer's disease
Alzheimers disease
Anatomy & physiology
Atrophy
Brain
Brain - diagnostic imaging
Brain - drug effects
Brain - metabolism
Brain - pathology
Clinical trials
Cognition Disorders - diagnostic imaging
Cognition Disorders - drug therapy
Cognition Disorders - metabolism
Cognition Disorders - pathology
Cognitive ability
Consent
Cyanocobalamin
Dementia
Dementia disorders
Diet
Dietary supplements
Disease control
Drug dosages
Female
Folic acid
Geriatrics
Geriatrics/Dementia
Homocysteine
Homocysteine - blood
Homocysteine - metabolism
Humans
Impairment
Magnetic Resonance Imaging
Male
Medical treatment
Memory
Mental Health/Alzheimer Disease
Mental Health/Cognitive Neurology
Mental Health/Dementia
Neurodegenerative diseases
Neurological Disorders/Alzheimer Disease
Neurological Disorders/Cognitive Neurology and Dementia
Neurology
NMR
Nuclear magnetic resonance
Nutrition
Older people
Pharmacology
Physiology
Radiography
Radiology and Medical Imaging/Magnetic Resonance Imaging
Randomization
Risk factors
Skull
Supplementation
Treatment Outcome
Vitamin B
Vitamin B Complex - therapeutic use
Vitamin B12
Vitamin B6
Vitamins
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQigMXRMujCy1YCAk4pPXmZZtbi6iKhAriUfVm-ZUSKZusNruV4C_wp5lJvFGDisqBWxJPstmZsedzPP6GkBeJg7AkCh-5rLBR6gyLTGZlZFOT6bxwieh2pZ194Ken4vxcfrpS6gtzwnp64F5xBzFAEp-w2IFjpd55yZnRAoF6ziXvtpfHgHo2k6l-DIZenOdho1zCZwfBLvuLpvb7_WpSOgpEHV__MCpPFlXTXgc5_8ycvBKKju-RuwFD0sP-3bfILV9vk63QS1v6KlBJv75Pfp0088YiWTOAyajCimgQqqj5QY_oZbnS87JuaQvXWwpAkCJtBG0Kqq2FaIRnjhqsIUHxizkYhMLhvKwcHbKOKG6zLJf4jfEN1fCE2jXz8qdHkS4JvoLDrjTIA_Lt-N3XtydRKL8QWS7kKtLCJgbQi8uYT53XM5EbwCtF7LSQ3MBUx2lQtCusLjyHE8cFk85YAxYXRZY8JJMaFL5DKOPS2NgalmQ5Ut4LpmeFlYCtRJoxnU9JsrGFsoGbHEtkVKpbcOMwR-lVq9CCKlhwSqLhrkXPzXGD_BGaeZBFZu3uAvibCv6mbvK3KXmGTqL6barD-KAOUyyfigSAU_K8k0B2jRrTdy70um3V-49n_yD05fNI6GUQKhpQh9VhywT8J2TtGknujiRhjLCj5h106Y1WWgUoL45lmqUzuHPj5tc306EZH4opebVv1q3iyOUHMSH-u4gEeI71GeD3H_X9ZtA99Fl4txhu5qMeNTLOuKUuv3f05zEu3Uv2-H9Y8wm506eDyIiJXTJZLdd-j9y2l6uyXT7txpTf6Ep9yw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Public Library of Science (PLoS) Journals Open Access
  dbid: FPL
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9NAEF5B4MAFaAs0UGCFEI-Di-PX7nJzKqJWCqVqS9SbtS-DpcSO4gRU_gJ_mhnbMbhqBNyc7KwTz-y8vLPfEPLSN-CWeGodE6baCYxyHRVq4ehAhTJKjc-rU2mTMTs-5hcX4uR3onhlB99ng3cNT_fnRW73652g4Ca55flRhCVco5Px2vKC7kZRczxu08yO-6lQ-ltb3JtPi_K6QPNqveQfDmh073__-n1ytwk1aVyvjS1yw-bbZCfOIc2eXdJXtCr-rN6qb5OtRsdL-qYBon67Q34eFrNCI9QzhKLOGPupgaOj6pIO6SRbylmWl_RsWnwvKYSR9BTCVlqkNNYafBlCUBg6xA4UNF4uChAnhcuP2dTQg3XNEj0Ca5Qt8A3lexrDHXJTzLIfFkmqEvopXJ6jjjwgn0cfzg8OnaZ5g6MZF0tHcu0riH1M6NrAWDngkYJoJ_WM5IIpSJSMBIGZVMvUMvhgGHeFUVrBeuFp6D8kvRz4tkuoy4TSnlauH0YImM9dOUi1gMiMB6Eroz7x1zJNdINsjg02pkm1Xccgw6k5nqAgkkYQfeK0s-Y1ssdf6Ie4XFpaxOWuvgCJJ42aJx4E0NZ3PQNmMLDGCuYqyTGtjJhgg7BPnuNiS-pDrq11SeIAm68ifGCfvKgoEJsjx-KfL3JVlsnRp8k_EJ2ddoheN0RpAezQsjlwAc-EmF8dyr0OJVgY3RneRdVYc6VMIEb0PBGEwQBmrtXl-mHaDuNNsaAvt8WqTBgiAYJH8TaTCAjusbsD_P6jWv9a3nuQOEAqDpNZRzM7wumO5NnXCjzdw41_4T7e_ExPyJ26REQ4Lt8jveViZZ-S2_rbMisXzyqL8wtSMIGq
  priority: 102
  providerName: Public Library of Science
Title Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial
URI https://www.ncbi.nlm.nih.gov/pubmed/20838622
https://www.proquest.com/docview/1292294541
https://www.proquest.com/docview/755180032
https://www.proquest.com/docview/954574780
https://pubmed.ncbi.nlm.nih.gov/PMC2935890
https://doaj.org/article/2161e302d8704ede970ba80499679715
http://dx.doi.org/10.1371/journal.pone.0012244
Volume 5
WOSCitedRecordID wos000281687100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: DOA
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: M~E
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Advanced Technologies & Aerospace Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: P5Z
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/hightechjournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Agricultural Science Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: M0K
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/agriculturejournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: M7P
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Engineering Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: M7S
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Environmental Science Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: PATMY
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/environmentalscience
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: 7X7
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Materials Science Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: KB.
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/materialsscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Nursing & Allied Health Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: 7RV
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/nahs
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: BENPR
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Publicly Available Content Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: PIMPY
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: 8C1
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVATS
  databaseName: Public Library of Science (PLoS) Journals Open Access
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: FPL
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://www.plos.org/publications/
  providerName: Public Library of Science
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLbYxgMvwDZghVEshLg8ZEtzs80LaqtVm3Yh6kY1eIkSOxmR2qQ0HWj8Bf405zhuIWhcJF6O0vo4bezjc3GOv0PIM1eBWeJZaik_k5anEttKfCks6SV-HGTK5fpU2uiInZzw83MRmg23yqRVLnSiVtSqlLhHvgt2yXGE53udN9NPFlaNwrerpoTGCllDlARXp-6FC00MazkIzHE5l3V2zezsTMsi3anfKXkNc6RR-5e6eXU6LqvrHM9f8yd_MkiDO__7KHfJbeOK0m4tO-vkRlpskM1uAWH45Io-pzo5VO-6b5B1owMq-tIAVb_aJN_2y0kpEQoaXFXrCOutgSGkyRXt0VE-jyd5UdHTcfmlouBm0iG4tbTMaFdKsHUIUaFoDytU0O58VsJ0U7g8zseK9hc5TfQAtFU-wx3M17QLdyhUOcm_psiiU-zHcHmGa-geeTfYO-vvW6a4gyUZF3Mr5tJNwDdSvp16Ko07PEjAG8ocFXPBEgikVAwTqDIZZymDD4pxW6hEJiBPPPPd-2S1gIncItRmIpGOTGzXDxBQn9txJ5MCPDfu-XYctIi7mONIGuRzLMAxjvTrPAYRUD3iEUpGZCSjRaxlr2mN_PEX_h6Kz5IXcbv1F-XsIjJqIHLAwU5d21GgJr1UpYLZScwx7AyYYB2_RZ6g8EX1Idil9om6HhZnRXjBFnmqORC7o8DkoIv4sqqig7ejf2A6HTaYXhimrIThkLE5kAHPhJhgDc7tBidoINlo3sKlshiVKvoh4NBzsQSub6bLZrwpJvwVaXlZRQyRAsHiOL9nEeD8Y_UH-P0H9Xpcjr0DgQWE6tCZNVZqY3KaLUX-UYOrO5gYIOyHf_7jj8itOo1EWDbfJqvz2WX6mNyUn-d5NWuTFTYcIT1nmnKgvN9pk7Xe3kk4bOuNH6CD8AjoYW8H6LF92NbaS9NToKH_AXqEB8fh---I4KAH
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF5VBQkuQFuggUJXiFcPbh2_dhcJoaRQJWpaUFui3sx6d10sJXaIU6ryF_gv_EZm_AgYlcelB262d9aJx7PfzHjnQchjV4Na4rGxtB8ry9ORbUW-EpbyIl8GsXZ5kZU2HLD9fX58LN4tkG91LgyGVdaYWAC1zhR-I98CveQ4wvO99qvJJwu7RuHuat1CoxSLXXN-Bi5b_rL_Gt7vE8fZeXO03bOqrgKWYlzMLMmVG4FS1r5tPG1kmwcRqOHY0ZILFoEFryWggI6VjA2DE824LXSkIngQHmOXCID8K4DjbQwhYwfDGvlhVhBU6Xkua29V0rA5yVKzWe5heQ31V3QJmOuCxckoyy8ydH-N1_xJAe7c_N9Yd4vcqExt2inXxhJZMOkyWemkcpaNz-lTWgS_FrsKy2SpwricPq8KcW-skK-9bJwpLHUNprg1wH5yoOhpdE67dJjM5DhJc3o4ys5yCmY0PQCznWYx7SgFuhxLcGjaxQ4ctDObZiDOFA73kpGm23XMFu0DGidT_EL7gnbgDqnOxskXgyRFCsEIDo8QI26T95fCqztkMQXBWSXUZiJSjops1w-wYQC3ZTtWAixT7vm2DFrErWUqVFVld2wwMgqL7UoGHl7J8RAlMawksUWs-axJWdnkL_RdFNc5LdYlLy5k05OwgrnQAQfCuLajQQ14RhvB7EhydKsDJljbb5F1FPawTPKdo2vY8bD5LJZPbJFHBQXWJkkx-OlEnuZ52H87_Aeiw4MG0bOKKM6AHUpWCSfwTFjzrEG51qAEhFWN4VVcmjVX8vDHgoKZ9ZK7eJjOh_GmGNCYmuw0DxlWQgSN6vyeRIBzg90t4Pfvlut_znsHHCceODCZNZCh8XKaI2nysSge72Dgg7Dv_fmPr5NrvaO9QTjo7-_eJ9fLkBlh2XyNLM6mp-YBuao-z5J8-rBAQEo-XDZufAf72_SE
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELaqghAXoC3QhUItxPOQNpuXHSSEdluqrlpK1Zaqt-DYTom0Gy-bXaryF_hH_Dpm8oKg8rj0wC2Jx9nNZPzNTDwPQh67CtQST7Sl_ERanoptK_ZlaEkv9kWQKJcXWWnHu2xvj5-chPtz5FudC4NhlTUmFkCtjMRv5Ouglxwn9Hyvu55UYRH7m1uvx58s7CCFO611O41SRHb0-Rm4b_mrwSa86yeOs_XmaGPbqjoMWJLxcGoJLt0YFLTybe0pLbo8iEElJ44SPGQxWPNKACKoRIpEMzhRjNuhimUMD8UT7BgB8H-FuSDFmKW-0YSXwKwgqFL1XNZdryRjbWwyvVbuZ3ktVVh0DGj0wvx4aPKLjN5fYzd_UoZbN_9nNt4iNyoTnPbKNbNA5nS2SJZ6mZia0Tl9Soug2GK3YZEsVNiX0-dVge4XS-TrthkZiSWwwUS3drHPHBgAND6nfXqcTsUozXJ6ODRnOQXzmh6AOU9NQntSgo7H0hyK9rEzB-1NJwbEnMLh23So6EYdy0UHgNLpBL_cvqQ9uEOmzCj9opGkSC0YwuERYsdt8v5SeHWHzGcgRMuE2iyMpSNj2_UDbCTAbdFNZAgWK_d8WwQd4tbyFcmq4js2HhlGxTYmA8-v5HiEUhlVUtkhVjNrXFY8-Qt9H0W3ocV65cUFMzmNKviLHHAstGs7CtSDp5UOmR0Lju52wELW9TtkFQU_KpN_G9SNeh42pcWyih3yqKDAmiUZiu2pmOV5NHh3_A9EhwctomcVUWKAHVJUiSjwTFgLrUW50qIE5JWt4WVcpjVX8ujH4oKZ9fK7eJg2w3hTDHTMtJnlEcMKiaBpnd-ThOD0YNcL-P27JRY0vHfAoeKBA5NZCyVaL6c9kqUfi6LyDgZEhPa9P__xVXIN4CLaHezt3CfXy0ia0LL5CpmfTmb6AbkqP0_TfPKwAENKPlw2bHwH2wr83w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Homocysteine-Lowering+by+B+Vitamins+Slows+the+Rate+of+Accelerated+Brain+Atrophy+in+Mild+Cognitive+Impairment%3A+A+Randomized+Controlled+Trial&rft.jtitle=PloS+one&rft.au=Smith%2C+A.+David&rft.au=Smith%2C+Stephen+M&rft.au=de+Jager%2C+Celeste+A&rft.au=Whitbread%2C+Philippa&rft.date=2010-09-08&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=5&rft.issue=9&rft.spage=e12244&rft_id=info:doi/10.1371%2Fjournal.pone.0012244&rft.externalDocID=A473860850
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon